Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P080011/S186

iWear oxygen presbyopia

CooperVision, Inc. · Decision date Aug 20, 2025

FDA DECISIONP080011/S186

What did the FDA approve?

FDA records P080011/S186 as a supplement to PMA P080011, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 20, 2025.

FDA approval order statement

approval for labeling change to add new private label brand name, iWear oxygen presbyopia. The name iWear oxygen presbyopia is intended for the multifocal lens design
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Ophthalmic
Decision date
Aug 20, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P080011/S186
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
APPR
Decision date
Aug 20, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

For the original device and its historical approval scope, see PMA P080011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P080011 · Original PMA

    BIOFINITY (COMFILCON A)

  2. P080011/S186 received

    Application receipt date recorded by FDA.

  3. P080011/S180 · Related supplement

    up&up Monthly Performance, up&up Monthly Performance XR, up&up Monthly Performance for Astigmatism, up&up Monthly Perfor

  4. P080011/S184 · Related supplement

    up&up Monthly Performance +

  5. P080011/S186 · FDA decision

    Normal 180 Day Track No User Fee

  6. P080011/S192 · Related supplement

    Biofinity Toric Multifocal and Biofinity XR Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  7. P080011/S191 · Related supplement

    Sofmed breathables XW NEXT

  8. P080011/S193 · Related supplement

    Biofinity XR Toric and Biofinity Toric Multifocal (Comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  9. P080011/S194 · Related supplement

    comfilcon A Soft (Hydrophilic) Contact Lenses for daily wear

  10. P080011/S195 · Related supplement

    Biofmity XR Torie (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  11. P080011/S196 · Related supplement

    Biofinity Sphere and Biofinity Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  12. P080011/S197 · Related supplement

    Biofinity Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  13. P080011/S198 · Related supplement

    Biofinity Toric Multifocal (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  14. P080011/S199 · Related supplement

    Biofinity Sphere, Biofinity XR Sphere, Biofinity Energys, Biofinity Toric, Biofinity XR Toric, Biofinity Multifocal; Bio

  15. P080011/S200 · Related supplement

    Biofinity Sphere, Biofinity XR Sphere, Biofinity Energys, Biofinity Toric, Biofinity XR Toric, Biofinity Multifocal; Bio

  16. P080011/S201 · Related supplement

    Biofinity Sphere; Biofinity XR Sphere; Biofinity Energys; Biofinity Toric; Biofinity XR Toric; Biofinity Multifocal

  17. P080011/S202 · Related supplement

    comflicon A Soft (Hydrophilic) Contact Lenses for Extended Wear

  18. P080011/S203 · Related supplement

    comfilcon A Soft (Hydrophilic) Contact Lenses for Extended Wear

  19. P080011/S204 · Related supplement

    BIOFINITY (COMFILCON A)

Timeline entries are records held by MedtechLedger for P080011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P080011

Product / regulatory recordCompanyPathwayDecision dateSource
CooperVision, Inc.PMA approvalNov 19, 2008FDA
CooperVision, Inc.PMA supplementJul 23, 2025FDA
CooperVision, Inc.PMA supplementAug 20, 2025FDA
CooperVision, Inc.PMA supplementSep 22, 2025FDA
CooperVision, Inc.PMA supplementDec 5, 2025FDA
CooperVision, Inc.PMA supplementDec 11, 2025FDA
CooperVision, Inc.PMA supplementJan 7, 2026FDA
CooperVision, Inc.PMA supplementFeb 2, 2026FDA
CooperVision, Inc.PMA supplementFeb 10, 2026FDA
CooperVision, Inc.PMA supplementMar 4, 2026FDA
CooperVision, Inc.PMA supplementMar 4, 2026FDA
CooperVision, Inc.PMA supplementMar 18, 2026FDA
CooperVision, Inc.PMA supplementApr 9, 2026FDA
CooperVision, Inc.PMA supplementMay 4, 2026FDA
CooperVision, Inc.PMA supplementJun 16, 2026FDA
CooperVision, Inc.PMA supplementJul 7, 2026FDA
CooperVision, Inc.PMA supplementSep 2, 2026FDA

Explore the linked device profile

Other records with product code LPM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

CooperVision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6101 Bollinger Canyon Rd., Suite 500, San Ramon, CA, 94583

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records